| Risk | High |
|---|---|
| Min SIP Amount | ₹500 |
| Expense Ratio | 0.92% |
| NAV | ₹12.94 (13 Jul 2020) |
|---|---|
| Fund Started | 10 Jul 2019 |
| Fund Size | ₹264 Cr |
| Name | Sector | Instrument | % Assets |
|---|---|---|---|
| Cipla Ltd. | Healthcare | Equity | 10.6% |
| Dr. Reddy's Laboratories Ltd. | Healthcare | Equity | 9.6% |
| Sun Pharmaceutical Inds. Ltd. | Healthcare | Equity | 9.2% |
| Divi's Laboratories Ltd. | Healthcare | Equity | 6.9% |
| Lupin Ltd. | Healthcare | Equity | 5.1% |
| Atul Ltd. | Chemicals | Equity | 4.9% |
| Zydus Wellness Ltd. | FMCG | Equity | 4.7% |
| Cadila Healthcare Ltd. | Healthcare | Equity | 4.6% |
| Biocon Ltd. | Healthcare | Equity | 4.3% |
| Apollo Hospitals Enterprise Ltd. | Healthcare | Equity | 3.9% |
Aditya Birla Sun Life Pharma & Healthcare Fund Direct Growth is a Equity Mutual Fund Scheme launched by Aditya Birla Sun Life Mutual Fund. This scheme was made available to investors on 10 Jul 2019. Dhaval Shah is the Current Fund Manager of Aditya Birla Sun Life Pharma & Healthcare Fund Direct Growth fund.The fund currently has an Asset Under Management(AUM) of ₹264 Cr and the Latest NAV as of 13 Jul 2020 is ₹12.94.
The Aditya Birla Sun Life Pharma & Healthcare Fund Direct Growth is rated High risk. Minimum SIP Investment is set to 500. Minimum Lumpsum Investment is 1000. Exit load of 0.5% if redeemed within 90 days.
The scheme seeks to provides long term capital appreciation by investing in equity/equity related instruments of the companies in the Pharmaceuticals, Healthcare and Allied sectors in India.